Enabling Rapid IND Delivery Through Strategic CMC Development of a PD-1/VEGF Bispecific Antibody
- Accelerating biologics CMC timelines through strategic, risk-based development approaches
- Balancing purification efficiency, manufacturability, and product variant control
- De-risking late-stage development through early product and process understanding